Steven Paul Wagner

US Patent:

20120223091, Sep 6, 2012

Filed:

Mar 4, 2011

Appl. No.:

12/932706

Inventors:

Gregg Bond - Beverly Hills CA, US
Steven Wagner - Agoura Hills CA, US
Kenneth A. Tarlow - Corte Madera CA, US

International Classification:

B65D 83/04

US Classification:

221 7

Abstract:

Cap with a hollow housing containing a count down mechanism so that when a person pushes down on the cap during the opening process, a rotational force within the housing causes the day and numerical count indices printed on cylinders within the housing to advance one station so that the day and count indices showing in viewing apertures located on the outside wall of the housing reflect the fact that an item such as a pill has been taken by the user. A preferred embodiment includes a ring release slide mechanism that allows the user to disengage the advancing mechanism so that the user can manually rotate the counting mechanism to initially set the indices to the correct location with respect to the viewing apertures and to be able to reset the indices if the user presses on the top cap housing accidentally.

US Patent:

52139620, May 25, 1993

Filed:

Jul 30, 1992

Appl. No.:

7/924417

Inventors:

William E. Van Nostrand - Irvine CA
Dennis D. Cunningham - Laguna Beach CA
Steven L. Wagner - Balboa Island CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12Q 170

US Classification:

435 71

Abstract:

Immunopurification of Protease Nexin-2 and. beta. amyloid precursor protein is disclosed. Methods of detecting Protease Nexin-2 and the use of these methods in the diagnosis of Alzheimer's disease and other conditions are also disclosed. Additionally, pharmaceutical preparations including Protease Nexin-2 or modified forms thereof are disclosed. Medical uses for the pharmaceutical preparations are also disclosed. These uses include the treatment and prevention of amyloid plaques in Alzheimer's disease and Down's Syndrome.

US Patent:

52701654, Dec 14, 1993

Filed:

Oct 15, 1991

Appl. No.:

7/779070

Inventors:

William E. Van Nostrand - Irvine CA
Dennis D. Cunningham - Laguna Beach CA
Steven L. Wagner - La Jolla CA

Assignee:

The Reagents of the University of California - Oakland CA

International Classification:

G01N 3353

US Classification:

435 71

Abstract:

A method of diagnosing a disease with cerebrovascular deposition of amyloid, including Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis-Dutch type and other amyloidoses, in a mammal is disclosed in which a sample of cerebrospinal fluid is obtained, the level of immunoreactivity toward a monoclonal antibody raised against native PN-2/. beta. APP or other amyloid precursor protein in the sample is measured, and this measured level is compared to the level of immunoreactivity toward this antibody in a sample from NOTICE OF GOVERNMENT SUPPORT This invention was made with Government support under Grant No. GM-31609 awarded by the National Institutes of Health. The Government has certain rights in this invention. American Cancer Society Grants CD 390 and BC 602/BE 22A provided further support for the development of this invention.

US Patent:

54279313, Jun 27, 1995

Filed:

Apr 27, 1993

Appl. No.:

8/056423

Inventors:

William E. Van Nostrand - Irvine CA
Dennis D. Cunningham - Laguna Beach CA
Steven L. Wagner - Balboa Island CA

Assignee:

Then Regents of the University of California - Oakland CA

International Classification:

C12P 2108
A61K 39395

US Classification:

435 702

Abstract:

Monoclonal antibody and the hybridoma producing the antibody are disclosed. The antibody is produced against an epitope on native secreted forms of. beta. APP. A characteristic of the antibody is that the antibody specifically binds to at least one protein in culture medium in which neuroblastoma cells have been grown. This protein co-migrates in non-reducing polyacrylamide gel electrophoresis with PN-2 isolated from human fibroblast cultures. Other characteristics of the antibody are that the antibody specifically binds to PN-2 and to the secreted form of. beta. APP lacking the Kunitz-type inhibitor domain, the antibody selectively binds to neuritic plaques, and the antibody is sufficiently sensitive to detect secreted forms of. beta. APP in CSF, down to a total concentration of the secreted forms of. beta. APP of 3. 75. mu. g/ml or lower.